APA (7th ed.) Citation

S, F., TJ, I., G, P., E, W., RR, P., & M, B. (2023). Re: Response letter to Sanofi's communication related to "the budget impact of enzyme replacement therapy in type 1 Gaucher disease in the United States". Journal of medical economics, 26(1), 581. https://doi.org/10.1080/13696998.2023.2197785

Chicago Style (17th ed.) Citation

S, Farahbakhshian, Inocencio TJ, Poorman G, Wright E, Pathak RR, and Bullano M. "Re: Response Letter to Sanofi's Communication Related to "the Budget Impact of Enzyme Replacement Therapy in Type 1 Gaucher Disease in the United States"." Journal of Medical Economics 26, no. 1 (2023): 581. https://doi.org/10.1080/13696998.2023.2197785.

MLA (9th ed.) Citation

S, Farahbakhshian, et al. "Re: Response Letter to Sanofi's Communication Related to "the Budget Impact of Enzyme Replacement Therapy in Type 1 Gaucher Disease in the United States"." Journal of Medical Economics, vol. 26, no. 1, 2023, p. 581, https://doi.org/10.1080/13696998.2023.2197785.